HIVe Home
ID#: PA-10-115      Posted: 16 Mar 2011
Indo-U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03) PA-10-115
Deadline: 16 Jun 2012
Apply Here
Type of Grant: Research
Topics/Fields of Support: Adjuvants, Animal model studies, Clinical trial site challenges, Human genomics, Immune escape, Innate immunity, Mucosal immunity, Novel immunogens, inserts and vectors, Prevention strategies, Social, ethical, access and regulatory issues, T cell immunity, Vaccine concepts and design, Viral Diversity, Other

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency—making important medical discoveries that improve health and save lives.

Thanks in large part to NIH-funded medical research, Americans today are living longer and healthier. Life expectancy in the United States has jumped from 47 years in 1900 to 77 years today, and disability in people over age 65 has dropped dramatically in the past 3 decades. In recent years, nationwide rates of new diagnoses and deaths from all cancers combined have fallen significantly.

Scientific Leadership

NIH is the largest source of funding for medical research in the world, creating hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe.

NIH is made up of 27 Institutes and Centers, each with a specific research agenda, often focusing on particular diseases or body systems. NIH leadership plays an active role in shaping the agency's activities and outlook.

The Office of the Director is the central office at NIH, responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. The NIH Director, with a unique and critical perspective on the entire agency, is responsible for providing leadership to the Institutes and for constantly identifying needs and opportunities, especially for efforts that involve multiple Institutes. The NIH Director is assisted by the NIH Deputy Directors including the Principal Deputy Director, who shares in the overall direction of the agency's activities.

More than 80% of the NIH's budget goes to more than 300,000 research personnel at over 3,000 universities and research institutions. In addition, about 6,000 scientists work in NIH’s own laboratories, most of which are on the NIH main campus in Bethesda, Maryland. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research.

Successful biomedical research depends on the talent and dedication of the scientific workforce. NIH supports many innovative training programs and funding mechanisms  that foster scientific creativity and exploration. The goal is to strengthen our nation’s research capacity, broaden our research base, and inspire a passion for science in current and future generations of researchers.

Visit web site


Scientific cooperation between India and the U.S. has taken place under a variety of bilateral umbrella agreements, including the Indo-U.S. Science and Technology (S&T) Sub-Commission, the Gandhi-Reagan S&T Initiative, the U.S.-India Fund, and the current S&T Cooperation Agreement.  Building upon these agreements and initiatives, representatives of the United States and the Government of India signed a Memorandum of Understanding on July, 9 1987 implementing the Indo-U.S. Vaccine Action Program (VAP) in order to expand collaborative vaccine research.  The goal of the VAP is to support collaborative vaccine-related research projects that ultimately reduce the burden of infectious diseases of importance in India, the U.S., the South Asian region and globally. Applications are encouraged from organizations/institutions that propose to conduct vaccine-related research through well-established collaborations with Indian investigators on the following: dengue, influenza (including avian influenza), HIV/AIDS, and tuberculosis.  Basic, translational, clinical, or epidemiological vaccine research may be proposed. Clinical trials will not be supported by this initiative.

Research Objectives

Collaboration in science and technology has been an enduring feature of the U.S.-India relationship for over three decades, and cooperation in the health sciences has been particularly prominent.  This new initiative is designed to further advance scientific collaborations between US and Indian investigators, specifically in the area of vaccinology.

Special initiatives have been undertaken over the years in an effort to advance cooperation with India more rapidly and effectively in some areas.  One of the most important and successful of these has been the Indo-U.S. Vaccine Action Program (VAP), a jointly administered and funded bilateral vaccine research program, which has supported approximately 35 collaborative research projects since its inception in 1987 as a part of a large umbrella of bilateral Science and Technology (S&T) activities between India and the U.S.  The VAP supports a broad spectrum of research in vaccinology, spanning laboratory-based research, epidemiological studies, development of vaccines and immunodiagnostic reagents, and delivery of vaccines. 

Under the VAP, U.S. and Indian scientists jointly develop and carry out collaborative vaccine research that is frequently jointly funded by sponsoring organizations in the U.S. and India.  All research is carried out within areas designated as VAP priorities by the VAP Joint Working Group (JWG), which is comprised of high-ranking scientists and officials of both countries.  The JWG establishes the policies and scientific directions for the program, makes decisions on major activities, and provides scientific oversight.   

The continued work of the VAP program is an important recognition that vaccines are among the most cost-effective of health technologies and their widespread use in both countries is key to controlling the burden of vaccine-preventable diseases.  With the emergence of new infectious diseases and increasing attention to health programs which promote child survival, there is renewed interest in attacking this important category of diseases across the full spectrum of scientific, medical and public health disciplines.  

Research Scope

This initiative offers to support VAP research activities and encourages research leading to the development of new and improved vaccines and related products and technologies to combat important infectious diseases of importance in India, the U.S., the South Asian region and globally.  While applicants must provide evidence of ongoing or proposed scientific collaborations specific to the research proposed in the grant application, this initiative will not require joint application, review and funding of proposals by the U.S. and India as was required in previous VAP-supported research projects. Standard NIH application and review procedures will be followed. NIAID will fund the grants supported by this FOA. 

Any area of basic, translational, clinical, or epidemiological research may be proposed under this program.  Examples of possible research topics include, but are not limited to:

  • Discovery, demonstration of the proof of principle, development of novel manufacturing processes, evaluation of the safety and efficacy and demonstration of the effectiveness of the use of new and improved vaccines to prevent:

    1.     HIV/AIDS

    2.     Tuberculosis

    3.     Pandemic and interpandemic influenza

    4.     Dengue and Dengue Hemorrhagic Fever (DHF)

  • Development of adjuvants 
  • New manufacturing and vaccine delivery technology
  • Effectiveness of the introduction of new and improved vaccines into public health immunization programs.
  • Epidemiology of disease in the human population.

Note: Clinical trials will not be supported by this FOA.

See Section VIII, Other Information - Required Federal Citations, for policies related to this announcement.
See grant posting webpage on NIH website for application details.


Eligibility Information

1. Eligible Applicants

1.A. Eligible Institutions

The following organizations/institutions are eligible to apply:

Public/State Controlled Institutions of Higher Education

Private Institutions of Higher Education

Hispanic-serving Institutions

Historically Black Colleges and Universities (HBCUs)

Tribally Controlled Colleges and Universities (TCCUs)

Alaska Native and Native Hawaiian Serving Institutions

Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)

Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

Small Businesses

For-Profit Organizations (Other than Small Businesses)

State Governments

Indian/Native American Tribal Governments (Federally Recognized)

Indian/Native American Tribally Designated Organizations

County Governments

City or Township Governments

Special District Governments

Independent School Districts

Public Housing Authorities/Indian Housing Authorities

U.S. Territory or Possession

Indian/Native American Tribal Governments (Other than Federally Recognized)

Regional Organizations

Non-domestic (non-U.S.) Entities (Foreign Organizations) in India only.


Eligible Agencies of the Federal Government

Faith-based or Community-based Organizations

1.B. Eligible Individuals

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application for projects that require a “team science” approach and therefore clearly do not fit the single-PD/PI model. Additional information on the implementation plans and policies and procedures to formally allow more than one PD/PI on individual research projects is available at All PDs/PIs must be registered in the NIH electronic Research Administration (eRA) Commons prior to the submission of the application (see for instructions).

The decision of whether to apply for a grant with a single PD/PI or multiple PDs/PIs is the responsibility of the investigators and applicant organizations and should be determined by the scientific goals of the project. Applications for grants with multiple PDs/PIs will require additional information, as outlined in the instructions below. When considering the multiple PD/PI option, please be aware that the structure and governance of the PD/PI leadership team as well as the knowledge, skills and experience of the individual PDs/PIs will be factored into the assessment of the overall scientific merit of the application. Multiple PDs/PIs on a project share the authority and responsibility for leading and directing the project, intellectually and logistically. Each PD/PI is responsible and accountable to the grantee organization, or, as appropriate, to a collaborating organization, for the proper conduct of the project or program, including the submission of required reports. For further information on multiple PDs/PIs, please see

2. Cost Sharing or Matching

This program does not require cost sharing as defined in the current NIH Grants Policy Statement.

3. Other-Special Eligibility Criteria

Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.

Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Beginning with applications intended for the January 25, 2009 official submission due date, all original new applications (i.e., never submitted) and competing renewal applications are permitted only a single amendment (A1). See and NOT-OD-09-016. Original new and competing renewal applications that were submitted prior to January 25, 2009 are permitted two amendments (A1 and A2). For these “grandfathered” applications, NIH expects that any A2 will be submitted no later than January 7, 2011, and NIH will not accept A2 applications after that date.

Renewals. The R03 is not renewable.

Small grant support may not be used for thesis or dissertation research.


Agency Contacts :

We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:

Scientific/Research Contact:
Edward McSweegan, Ph.D.
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Room 3800, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
Telephone: (301) 402-8370, FAX:  (301) 402-0659

Financial or Grants Management Contact:
Ms. Ann Devine
Division of Extramural Activities

National Institute of Allergy and Infectious Diseases
Room 2114, MSC-7614
6700-B Rockledge Drive
Bethesda, MD 20892-7614
Telephone: (301) 402-5601, Fax: 301-493-0597